RecruitingPHASE1, PHASE2NCT05989958

The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure

Studying Acute liver failure

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hexaell Biotech Co., Ltd.
Principal Investigator
YU Chen, MD
Beijing YouAn Hospital
Intervention
HepaCure(combination_product)
Enrollment
92 enrolled
Eligibility
18-65 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05989958 on ClinicalTrials.gov

Other trials for Acute liver failure

Additional recruiting or active studies for the same condition.

See all trials for Acute liver failure

← Back to all trials